Interstitial Lung Disease News and Research

RSS

Interstitial lung disease (ILD) is a broad group of lung diseases comprising of more than a hundred distinct disorders. All of these involve scarring or inflammation of the interstitial lung tissue and affect the volume of oxygen that can reach the bloodstream via the respiratory system.

Chinese researchers report first clinical trial based on autologous lung stem cell transplantation

A research team from Tongji University in China have made a breakthrough in human lung regeneration technology. For the first time, researchers have regenerated patients' damaged lungs using autologous lung stem cell transplantation in a pilot clinical trial.

9 Feb 2018

Exoskeleton device helps man with disabling condition to complete 10K race

Martin Jarry was a police officer in Quebec. He coached a youth hockey team. He was used to being active, used to working out, used to being strong. But when Jarry was diagnosed with inclusion body myositis (IBM), he had to do some serious re-evaluating of his activities.

10 Aug 2017

Researchers develop potential stem cell treatment for several lung conditions

A team of scientists from the UNC School of Medicine and North Carolina State University has developed promising research towards a possible stem cell treatment for several lung conditions, such as idiopathic pulmonary fibrosis (IPF), chronic obstructive pulmonary disease (COPD), and cystic fibrosis -- often-fatal conditions that affect tens of millions of Americans.

3 Aug 2017

New survey reveals emotional, practical challenges facing people with idiopathic pulmonary fibrosis

New results from a global survey supported by Boehringer Ingelheim reveal the emotional and practical challenges facing people with idiopathic pulmonary fibrosis (IPF).

24 Jul 2017

Statin medications can cause necrotizing myopathy in some patients

Statin medications, such as Crestor, Lipitor, and other lipid-lowering medications, have been prescribed increasingly in recent years to reduce cardiovascular disease and mortality in high risk individuals.

6 Jun 2017

Novartis, Bristol-Myers Squibb collaborate to examine combination therapies for metastatic colorectal cancer

Novartis today announced it has entered into a clinical research collaboration in which Bristol-Myers Squibb will investigate the safety, tolerability, and efficacy of Mekinist (trametinib) in combination with Opdivo (nivolumab) and Opdivo + Yervoy (ipilimumab) regimen as a potential treatment option for metastatic colorectal cancer in patients with microsatellite stable tumors where the tumors are proficient in mismatch repair (MSS mCRC pMMR).

5 Jun 2017

Takeda announces accelerated approval from FDA for new lung cancer treatment

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that ALUNBRIG (brigatinib) has received Accelerated Approval from the U.S. Food and Drug Administration for the treatment of patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer who have progressed on or are intolerant to crizotinib.

28 Apr 2017

Two thirds of IPF patients report being involved during the decision-making process for the most appropriate treatment

New results from a global survey of over 150 people living with idiopathic pulmonary fibrosis (IPF), a life-threatening rare lung disease, demonstrate that while many patients were involved in treatment decisions, opportunities exist to improve the level of dialogue between patients and healthcare professionals.

28 Feb 2017

Increasing idiopathic pulmonary fibrosis research

IPF is an incurable lung condition with the average life expectancy following diagnosis being just three years. It’s one of the many types of interstitial lung disease (ILD). Interstitial means that the disease affects the interstitium, a lace-like network of tissue that supports the air sacs (alveoli) in your lungs.

From Asthma + Lung UK 25 Jan 2017

Researchers crack genetic code of lung tissues to identify novel targets for treating IPF

Researchers cracked the complete genetic code of individual cells in healthy and diseased human lung tissues to find potential new molecular targets for diagnosing and treating the lethal lung disease Idiopathic Pulmonary Fibrosis (IPF).

8 Dec 2016

FDG PET-CT imaging helps assess anatomical structure and metabolic activity in patients with GLILD

A new proof of concept study has shown that an imaging technique more commonly used to assess cancer patients may also be of help in assessing disease and treatment effects in patients with inflammatory diseases.

30 Nov 2016

Boehringer Ingelheim and Duke expand collaboration to create largest patient registry for idiopathic pulmonary fibrosis (IPF)

Boehringer Ingelheim Pharmaceuticals, Inc. and the Duke Clinical Research Institute (DCRI) announced today the expansion of the Idiopathic Pulmonary Fibrosis – PROspective Outcomes (IPF-PRO) Registry, a patient registry developed to uncover insights into IPF, a rare and serious lung disease. The expansion will increase the study enrollment from 300 patients at 18 study sites to 1,500 patients at approximately 45 sites, creating the largest registry of newly diagnosed IPF patients.

29 Aug 2016

European Commission approves extended indication for Amgen's Kyprolis (carfilzomib) for the treatment of relapsed multiple myeloma patients

Amgen has announced that the European Commission (EC) has approved a variation to the marketing authorization for Kyprolis® (carfilzomib) to include use in combination with dexamethasone alone for adult patients with multiple myeloma who have received at least one prior therapy. The extended indication marks the second approval for Kyprolis by the EC in less than a year.

6 Jul 2016

Boehringer Ingelheim presents new data on OFEV® (nintedanib) in idiopathic pulmonary fibrosis (IPF)

New analyses presented at the American Thoracic Society’s 2016 annual conference (ATS 2016) further add to the efficacy and safety profile of OFEV® (nintedanib) in idiopathic pulmonary fibrosis (IPF).

16 May 2016

Pulmonary hypertension impacts walking ability in SSc patients

The results of a meta-analysis show the adverse impact pulmonary hypertension has on the walking stamina of patients with systemic sclerosis.

6 May 2016

M10 peptide could help protect systemic sclerosis patients against fibrotic damage

The results of preclinical studies by investigators at the Medical University of South Carolina (MUSC) reported in the April 2016 issue of Translational Research suggest that the M10 peptide could help protect against fibrotic damage in patients with systemic sclerosis, particularly in those who develop interstitial lung diseases (ILD), its deadliest complication.

15 Apr 2016

AstraZeneca reports new Phase I extended follow-up data on osimertinib in NSCLC patients at ELCC 2016

AstraZeneca today reported new Phase I extended follow-up data on osimertinib in both first- and second-line treatment of patients with non-small cell lung cancer (NSCLC), at the European Lung Cancer Conference (ELCC) 2016. Late-breaker presentations reinforced the efficacy and safety profile for osimertinib previously seen in the AURA clinical trials programme.

15 Apr 2016

Understanding idiopathic pulmonary fibrosis: an interview with Michael Durheim, M.D.

IPF is a rare and fatal lung disease that causes permanent scarring of the lungs, leading to debilitating shortness of breath and cough in affected patients. It affects as many as 132,000 Americans, most commonly those over the age of 65.

4 Apr 2016

Systemic sclerosis: an interview with Dr Kristin Highland

Systemic sclerosis, also known as scleroderma, is a rare disease characterized by the thickening and scarring of connective tissue of multiple organs in the body

7 Mar 2016

AstraZeneca’s TAGRISSO (osimertinib) approved in EU for metastatic EGFR T790M mutation-positive NSCLC

AstraZeneca today announced that the European Commission (EC) has granted conditional marketing authorisation for TAGRISSO™ (AZD9291, osimertinib) 80mg once-daily tablets for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC).

4 Feb 2016